Regenxbio Stock Price, News & Analysis

AbbVie and REGENXBIO announced a partnership to develop RGX-314, a gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). REGENXBIO will complete ongoing trials, while AbbVie leads global development and commercialization. AbbVie will pay REGENXBIO $370 million upfront, with potential total payments of up to $1.38 billion based on milestones. They will share profits from U.S. sales equally, with AbbVie paying tiered royalties internationally. The deal is expected to close by the end of 2021, contingent on regulatory approvals.

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in upcoming virtual investor conferences. Key events include a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, and another at Chardan's 5th Annual Genetic Medicines Conference on October 5, 2021. Webcasts for these chats will be available on the company's website for 90 days post-event. REGENXBIO specializes in gene therapy utilizing its proprietary NAV Technology Platform, which includes over 100 AAV vectors aimed at various therapeutic applications.

REGENXBIO Inc. (Nasdaq: RGNX) has appointed Dr. Jean Bennett and Mr. George Migausky to its Board of Directors, effective September 3, 2021. Dr. Bennett is known for her expertise in gene therapy and has contributed significantly to the field, including the development of Luxturna®. Mr. Migausky brings over 30 years of financial and operational leadership experience. The appointments come as REGENXBIO advances its clinical programs, particularly RGX-314 for wet age-related macular degeneration. The company also announced the resignation of Luke M. Beshar from the board.

REGENXBIO (RGNX) reported $22 million in Q2 2021 revenue, up from $16.6 million in Q2 2020, driven by a $6.5 million increase in Zolgensma royalties. The company holds $593 million in cash as of June 30, 2021, positioning it well to fund operations through mid-2023. Ongoing clinical trials for RGX-314 and RGX-121 show promise, with interim data set for presentation at the Retina Society meeting. Meanwhile, the net loss rose to $57.6 million, reflecting increased R&D and G&A expenses. The firm aims to submit an IND for RGX-202 by year-end 2021.

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on August 9, 2021, at 4:30 p.m. ET to discuss its Q2 2021 financial results and operational highlights. Interested participants can join the call by dialing (855) 422-8964 or accessing the webcast on the company's website. REGENXBIO focuses on gene therapy using its proprietary NAV^® Technology Platform, which includes over 100 adeno-associated viral vectors. The company aims to develop a robust pipeline across various therapeutic areas.

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming virtual investor conferences in June 2021. The Bank of America 2021 Napa Biopharma Virtual Conference will feature a fireside chat on June 16, 2021, at 12:30 p.m. E.T. Additionally, the Raymond James Human Health Innovation Conference is scheduled for June 21, 2021. Investors can access the live webcast of the Bank of America event on REGENXBIO's website, with an archived replay available for 30 days thereafter. REGENXBIO focuses on gene therapy through its proprietary NAV Technology Platform.

REGENXBIO has announced positive interim data from the ongoing Phase I/II trial of RGX-121, a gene therapy for Mucopolysaccharidosis Type II (MPS II). Key findings include no serious drug-related adverse events and evidence of CNS activity in patients up to two years post-administration. Biomarkers indicate strong I2S enzyme activity, and most patients showed continued neurocognitive development. The company has initiated dosing in Cohort 3 at an increased dosage, further enhancing prospects for RGX-121 as a treatment option for MPS II.

REGENXBIO Inc. (Nasdaq: RGNX) will present at three upcoming virtual investor conferences in May 2021. The events include:

• Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 12:30 p.m. E.T.
• RBC Capital Markets 2021 Global Healthcare Virtual Conference on May 18, 2021, at 10:55 a.m. E.T.
• UBS Global Healthcare Virtual Conference on May 25, 2021, at 11:00 a.m. E.T.

Live webcasts will be accessible on the REGENXBIO website, with replays available for 30 days.

REGENXBIO reported Q1 2021 financial results with revenues increasing to $18.9 million from $17.6 million year-over-year, primarily driven by a rise in Zolgensma royalties. The company holds $657 million in cash and equivalents, sufficient for operations into late 2023. Progress in clinical trials includes ongoing enrollment in pivotal trials for RGX-314 for wet AMD and advancements in RGX-121 and RGX-111 programs. Net loss widened to $50.1 million compared to $40.0 million in Q1 2020, reflecting increased R&D investments.